A combination comprising a compound of Formula: Wherein: R 1 is hydrogen, C 1-3 alkyl, CH 2 OH, CH 2 -O-CH 3, CH 2 OCH 2 Ph, CH 2 CN, CN, halo or C OCH 3; R 2 is independently hydrogen, CN, CF 3, halo, SO 2 C 1-3 alkyl, C 1-3 alkyl or C≡CH; R 3 is hydrogen, C 1-2 alkyl, CF 3 or OH; R 4 is hydrogen, halo or C 1-3 alkyl; X is CR 4 or N; A is (CH 2) n -Het; or A is (CH 2) n -(CR a R b)-(CH 2) m -Het; R a is hydrogen or C 1-3 alkyl, wherein the C 1-3 alkyl may be further substituted with one or more halos; R b is C 1-3 alkyl; or R a and R b together with the carbon atom they are attached form a C 3-6 cycloalkyl group; or one of the carbon atoms in the C 3-6 cycloalkyl group formed by R a and R b may be replaced with oxygen to form an oxetane, tetrahydrofuryl or tetrahydropyranyl group; or one of the carbon atoms in the C 3-6 cycloalkyl group formed by R a and R b may be replaced with nitrogen to form a pyrrolidinyl or piperidinyl group; Het is: wherein Het may be substituted by one, two or three substituents chosen from: halo, C 1-5 alkyl, CN, CH 2 F, CHF 2, CF 3, C 3-6 cycloalkyl, (CH 2) n -O-C 1-3 alkyl, (CH 2) n -phenyl, (CH 2) n -pyridyl, pyrimidinyl, pyrazinyl, CH(CH 3)-O-C 1-3 alkyl, CH -C 1-5 alkyl, C(CH 3) 2 - R 5, C N(CH 3) p, N(C 1-3 alkyl) p, NH 2, C NH 2, oxetane, oxetane-CH 3, tetrahydrofuryl, tetrahydropyranyl, morpholinyl, or pyrazolyl; wherein the phenyl, pyrazolyl, and pyridyl substituent on the Het may be further substituted by one or two substituents chosen from: halo, CN, OCH 3, C 1-3 alkyl or CF 3; and the C 1-5 alkyl and C 3-6 cycloalkyl substituent on the Het may be further substituted by CN or OH; R 5 is CN, O-C 1-4 alkyl, (CH 2) m -OH, (CH 2) p -O-C -O-C 1-5 alkyl, or O-(CH 2) p -O-R 6; R 6 is C 1-4 alkyl or P 2 (CH 3) 2; n is independently 0, 1 or 2; m is independently 0, 1 or 2; p is independently 1 or 2; and y is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal antiinflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective β-adrenoceptor and α 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors. R 1 is hydrogen, C 1-3 alkyl, CH 2 OH, CH 2 -O-CH 3, CH 2 OCH 2 Ph, CH 2 CN, CN, halo or C OCH 3; R 2 is independently hydrogen, CN, CF 3, halo, SO 2 C 1-3 alkyl, C 1-3 alkyl or C≡CH; R 3 is hydrogen, C 1-2 alkyl, CF 3 or OH; R 4 is hydrogen, halo or C 1-3 alkyl; X is CR 4 or N; A is (CH 2) n -Het; or A is (CH 2) n -(CR a R b)-(CH 2) m -Het; R a is hydrogen or C 1-3 alkyl, wherein the C 1-3 alkyl may be further substituted with one or more halos; R b is C 1-3 alkyl; or R a and R b together with the carbon atom they are attached form a C 3-6 cycloalkyl group; or one of the carbon atoms in the C 3-6 cycloalkyl group formed by R a and R b may be replaced with oxygen to form an oxetane, tetrahydrofuryl or tetrahydropyranyl group; or one of the carbon atoms in the C 3-6 cycloalkyl group formed by R a and R b may be replaced with nitrogen to form a pyrrolidinyl or piperidinyl group; Het is: wherein Het may be substituted by one, two or three substituents chosen from: halo, C 1-5 alkyl, CN, CH 2 F, CHF 2, CF 3, C 3-6 cycloalkyl, (CH 2) n -O-C 1-3 alkyl, (CH 2) n -phenyl, (CH 2) n -pyridyl, pyrimidinyl, pyrazinyl, CH(CH 3)-O-C 1-3 alkyl, CH -C 1-5 alkyl, C(CH 3) 2 - R 5, C N(CH 3) p, N(C 1-3 alkyl) p, NH 2, C NH 2, oxetane, oxetane-CH 3, tetrahydrofuryl, tetrahydropyranyl, morpholinyl, or pyrazolyl; wherein the phenyl, pyrazolyl, and pyridyl substituent on the Het may be further substituted by one or two substituents chosen from: halo, CN, OCH 3, C 1-3 alkyl or CF 3; and the C 1-5 alkyl and C 3-6 cycloalkyl substituent on the Het may be further substituted by CN or OH; R 5 is CN, O-C 1-4 alkyl, (CH 2) m -OH, (CH 2) p -O-C -O-C 1-5 alkyl, or O-(CH 2) p -O-R 6; R 6 is C 1-4 alkyl or P 2 (CH 3) 2; n is independently 0, 1 or 2; m is independently 0, 1 or 2; p is independently 1 or 2; and y is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal antiinflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective β-adrenoceptor and α 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.